Tag: #LGMD2A/R1

Atamyo Therapeutics présentera un update Corporate et les avancées de son pipeline lors de 6 conférences à venir aux États-Unis et en Europe

Posted on by admin_ata
  • Stéphane Degove, CEO, fera un point sur Atamyo lors du 20ème forum Annual Biotech in Europe de Sachs à Bâle, à la 8ème Conférence Genetic Medicines de Chardan à New York et au Cell & Gene Meeting on the Mesa à Phoenix
  • Six communications à venir lors de congrès en Europe et aux Etats-Unis sur les programmes au stade clinique et en recherche ciblant les myopathies des ceintures (LGMD)
  • Une publication dans Nature Communications décrit le travail de l’équipe d’Isabelle Richard, CSO d’Atamyo, sur l’utilisation de l’intelligence artificielle (IA) pour concevoir une nouvelle génération de capsides pour des vecteurs de thérapie génique plus efficaces.

Evry, France (le 16 septembre 2024) – Atamyo Therapeutics, société de biotechnologie au stade clinique spécialisée sur le développement de thérapies géniques de nouvelle génération ciblant les dystrophies musculaires et les cardiomyopathies, a annoncé aujourd’hui sa participation à plusieurs conférences et des communications scientifiques clés sur ses programmes ciblant les limb-girdle muscular dystrophies (LGMDs).

Stéphane Degove, le CEO d’Atamyo, présentera un update corporate lors du 20ème Forum Sachs Annual Biotech in Europe, à la 8ème Chardan Conference on Genetic Medicines, et au Cell & Gene Meeting on the Mesa 2024

  • 20ème Forum Sachs Annual Biotech in Europe (25-26 septembre 2024 à Bâle, Suisse):
    • Présentation le 25 septembre à 11h40 (CET), dans la salle Ruby
  • 8ème Chardan Conference on Genetic Medicines (30 septembre-1er octobre 2024 à New York):
    • Présentation le 30 septembre à 11h00 (ET), dans la salle Embassy
  • Cell & Gene Meeting on the Mesa (7-9 octobre 2024 à Phoenix, USA)
    • Présentation le 8 octobre à 17h45 (US MST), dans la FLW Ballroom F

Deux communications scientifiques au 29ème Congrès Annuel de la World Muscle Society, au Centre de Congrès de Prague, République Tchèque, porteront sur les programmes d’Atamyo ciblant la LGMD-R9/2i.

  • “Preliminary results from a Phase 1-2 gene therapy study of ATA-100, AAV9 vector encoding FKRP, in patients with Limb Girdle Muscular Dystrophy R9.”
    • Présentation orale de S. Olivier (Atamyo), au Congress Hall le samedi 12 octobre 2024, entre 8h00 et 8h15 (CEST)
  • “MRI characterization of the cardiac involvement in LGMD2i/R9.”
    • JY Hogrel (Institute of Myology, Paris) et al., Poster numéro 87P au Forum Hall le mercredi 9 octobre 2024, de 17h15 à 18h15 (CEST)

Deux communications scientifiques au 31ème Congrès Annuel de la European Society of Gene & Cell Therapy (22-25 octobre 2024 à La Nuvola, Rome, Italie) porteront sur les programmes d’Atamyo ciblant la LGMD-R9/2i :

  • “Development of a quantitative alpha-dystroglycan glycosylation test in patients with Limb Girdle Muscular Dystrophy R9 treated in ATA-001-FKRP open-label multicenter AAV trial.”
    • E Thevenot (Genethon) et al., poster P0088
  • “Natural history of limb girdle muscular dystrophy R9: two-year follow-up of a European cohort.”
    • S. Olivier (Atamyo) et al., poster numéro P0264

Deux communications sur deux programmes d’Atamyo ciblant les LGMD seront presentées à la Conference ASGCT’s Breakthroughs in Muscular Dystrophy, les 19-20 novembre, 2024, in Chicago, Etats-Unis.

  • “Development of Gene Therapy for LGMD-R9.”
    • Présentation orale par E. Gicquel (Genethon), le 19 novembre 2024, de 17h15 à 17h30 (US CDT), Great Lakes East Ballroom au Westin Michigan Avenue Hotel
  • “Overcoming Phenotypic Variability in Dystrophic Models: A Machine Learning Method for Refined Gene Therapy Evaluation.”
    • E. Brureau (Genethon) et al., poster P27, session du 16 novembre 2024, 8h00-19h00 (US CDT), salle Great Lakes East, au Westin Michigan Avenue Hotel

Publication dans Nature Communications sur un vecteur de thérapie génique de nouvelle génération ciblant les pathologies musculaires, utilisant une méthode d’AI prédictive pour améliorer l’efficacité et la tolérance

  • “An engineered AAV targeting integrin alphaV beta 6 presents improved myotropism across species,” par Ai Vu Hong (Genethon), et al., a été publié dans Nature Communications (https://doi.org/10.1038/s41467-024-52002-4). Cet article décrit le developpement de la capside de nouvelle generation LICA-1 par l’équipe d’Isabelle Richard, Ph.D., Directrice Scientifique d’Atamyo, au sein du département des Dystrophies musculaires progressives de Généthon.

Atamyo a des droits sur la capside LICA-pour les indications dans les cardiomyopathies.

A propos d’Atamyo Therapeutics

Atamyo Therapeutics est une biopharma au stade clinique, dédiée au développement d’une nouvelle génération de thérapies géniques sûres et efficaces pour lutter contre les dystrophies musculaires et les cardiomyopathies. Spin-off du pionnier en thérapie génique Généthon, Atamyo s’appuie sur l’expertise unique en matière de thérapie génique à base d’AAV (virus adéno-associé) et de compréhension des dystrophies musculaires, développés au sein du laboratoire des Dystrophies musculaires progressives de Généthon. Les programmes les plus avancés d’Atamyo portent sur différentes formes de dystrophies musculaires des ceintures (LGMD), dont deux programmes au stade clinique ciblant les LGMD-R9 et -R5. Le nom de l’entreprise est inspiré de deux mots : « Atao » qui signifie en langue celtique « toujours » ou « pour toujours » et « myo- » qui est la racine grecque désignant les muscles. « Atamyo » traduit l’engagement de la société à améliorer la vie des patients atteints de maladies neuromusculaires grâce à des traitements efficaces tout au long de leur vie.

Pour plus d’informations, visitez le site : www.atamyo.com

Contact U.S. :

Charles Craig, Opus Biotech Communications

charles.s.craig@gmail.com, 404-245-0591

Contact en Europe: contact@atamyo.com

Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe

Posted on by admin_ata
  • CEO Stephane Degove will provide corporate overviews at Sachs’ 20th Annual Biotech in Europe Forum in Basel, Chardan’s 8th Annual Genetic Medicines Conference in New York City, and the Cell & Gene Meeting on the Mesa in Phoenix.
  • The company also will make 6 presentations on its limb-girdle muscular dystrophy (LGMD) clinical development and research programs at 3 scientific conferences in the US and Europe.
  • A publication in Nature Communications describes the work of  CSO Isabelle Richard team on the use of artificial intelligence (AI) to design a new generation of capsids for more effective gene therapy vectors

Evry, France (September 16, 2024) – Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation in six upcoming conferences in the US and Europe to highlight recent developments in its programs targeting limb-girdle muscular dystrophies (LGMDs).

Atamyo CEO Stephan Degove will provide a corporate overview at Sach’s 20th Annual Biotech in Europe Forum, Chardan’s 8th Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa 2024.

  • Sach’s 20th Annual Biotech in Europe Forum, held in Basel, Switzerland, on September 25-26, 2024: 
    • Presentation on September 25, at 11:40 am (CEST), in the Ruby Room.
  • Chardan’s 8th Annual Genetic Medicines Conference, held in New York City, on September 30 and October 1, 2024:
    • Presentation on September 30 at 11:00 am (US EDT), in the Embassy Room.
  • Cell & Gene Meeting on the Mesa, held in Phoenix, AZ, on October 7-9, 2024:
    • Presentation on October 8, at 5:45pm (US MST), at the FLW Ballroom F.

Two communications at the 29th Annual Congress of the World Muscle Society, October 8-12, 2024, in the Prague Congress Centre, Prague, Czech Republic, will describe Atamyo’s LGMD programs.

  • “Preliminary results from a Phase 1-2 gene therapy study of ATA-100, AAV9 vector encoding FKRP, in patients with Limb Girdle Muscular Dystrophy R9.”
    • Oral presentation by S. Olivier (Atamyo), at Congress Hall on Saturday, October 12, 2024, 8 am – 8:15 am (CEST)
  • “MRI characterization of the cardiac involvement in LGMD2i/R9.”
    • JY Hogrel (Institute of Myology, Paris) et al., Poster Board Number 87P at Forum Hall, on Wednesday, October 9, 2024, 5:15 pm – 6:15 pm (CEST).

Two communications at the European Society of Gene & Cell Therapy 31st Annual Congress, October 22-25, 2024 in La Nuvola, Rome, Italy, will describe Atamyo’s LGMD programs. Both posters will be presented during Poster Session II on Wednesday 23 October, 1:30 pm to 3 pm (CEST)

  • “Development of a quantitative alpha-dystroglycan glycosylation test in patients with Limb Girdle Muscular Dystrophy R9 treated in ATA-001-FKRP open-label multicenter AAV trial.”
    • E Thevenot (Genethon) et al., Poster number P0088
  • “Natural history of limb girdle muscular dystrophy R9: two-year follow-up of a European cohort.”
    • S Olivier (Atamyo) et al., Poster number P0264

Two communications on Atamyo’s LGMD programs will be presented at the ASGCT’s Breakthroughs in Muscular Dystrophy Conference, November 19-20, 2024, in Chicago, IL.

  • “Development of Gene Therapy for LGMD-R9.”
    • Oral presentation by E. Gicquel (Genethon), on November 19, 2024, 5:15 p.m. – 5:30 p.m. (US CDT), Great Lakes East Ballroom at the Westin Michigan Avenue Hotel.
  • “Overcoming Phenotypic Variability in Dystrophic Models: A Machine Learning Method for Refined Gene Therapy Evaluation.”
    • E. Brureau (Genethon) et al. Poster P27. Session on November 16, 2024, 8 a.m.-7 p.m. (US CDT), Great Lakes East, at the Westin Michigan Avenue Hotel

Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety

“An engineered AAV targeting integrin alphaV beta 6 presents improved myotropism across species,” by Ai Vu Hong (Genethon), et al., was published in Nature Communications (https://doi.org/10.1038/s41467-024-52002-4). The paper describes development of the next-generation LICA-1 capsid by Isabelle Richard, Ph.D., Atamyo’s Chief Scientific Officer, and her Progressive Muscular Dystrophies Team at Genethon. Atamyo has rights to the LICA-1 capsid for cardiomyopathies indications.

About Atamyo Therapeutics

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD2I/R9 and LGMD2C/R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. For more information visit www.atamyo.com

European contact: contact@atamyo.com

U.S. Contact: Charles Craig, Opus Biotech Communications

Charles.s.craig@gmail.com, 404-245-0591

Atamyo Therapeutics annonce des présentations scientifiques sur ses programmes LGMD et sa participation à des conférences

Posted on by admin_ata
  • Cinq communications sur ses programmes LGMD seront présentées au congrès Myology 2024
  • Présentation corporate par son CEO Stephane Degove à BioEquity Europe 2024

Evry, France (April 22, 2024) – Atamyo Therapeutics, une entreprise biopharmaceutique spécialisée dans le développement de thérapies géniques de nouvelle génération ciblant des maladies neuromusculaires, a annoncé aujourd’hui des communications scientifiques sur ses programmes ciblant les limb-girdle muscular dystrophies (LGMDs) et sa participation à des conférences.

Cinq communications scientifiques au 8ème Congrès International Myology (22-24 avril 2024 à Paris).

Cinq communications décrivant les programmes d’Atamyo ciblant les LGMDs seront présentées au 8ème Congrès International Myology:

  1. Development of gene therapy for three prevalent forms of LGMD
  • Présentation orale par E. Giquel (Genethon), au Amphithéâtre Havane, le 24 avril 2024, à 11h00

2. Heart toxicity can be induced in rats after injection of high level of AAV expressing γ–sarcoglycan using the Desmin and MHCK7 but can be prevented by the tMCK promoter

  • J Poupiot (Genethon) et al., poster numéro P331, Therapeutics

3. Evaluation of gene transfer efficiency in a mild model of dystrophic muscle disorder performed by machine learning and linear discriminant analysis

  • A Brureau (Genethon) et al., poster numéro P117, Muscle Function session

4. Lipid metabolism is disrupted in mouse and human models of FKRP deficiency, and rescued after FKRP gene transfer

  • E Gicquel (Genethon) et al., poster numéro P296, Muscular Dystrophy session

5. FKRP related Limb Girdle Muscular Dystrophy: A biomarker identification study

  • S Campuzano (Genethon) et al., poster numéro P293, Muscular Dystrophy session

Atamyo participera à la conférence BioEquity Europe (12-14 mai à San Sebastian, Espagne).

Stéphane Degove, le CEO d’Atamyo, présentera un update corporate le 14 mai à 11:20, dans la salle 4+5

A propos d’Atamyo Therapeutics

Atamyo Therapeutics est une biopharma au stade clinique, dédiée au développement d’une nouvelle génération de thérapies géniques sûres et efficaces pour lutter contre les dystrophies musculaires et les cardiomyopathies. Spin-off du pionnier en thérapie génique Généthon, Atamyo s’appuie sur l’expertise unique en matière de thérapie génique à base d’AAV (virus adéno-associé) et de compréhension des dystrophies musculaires, développés au sein du laboratoire des Dystrophies musculaires progressives de Généthon. Les programmes les plus avancés d’Atamyo portent sur différentes formes de dystrophies musculaires des ceintures (LGMD), dont deux programmes au stade clinique ciblant les LGMD-R9 et -R5. Le nom de l’entreprise est inspiré de deux mots : « Atao » qui signifie en langue celtique « toujours » ou « pour toujours » et « myo- » qui est la racine grecque désignant les muscles. « Atamyo » traduit l’engagement de la société à améliorer la vie des patients atteints de maladies neuromusculaires grâce à des traitements efficaces tout au long de leur vie.

Pour plus d’informations, visitez le site : www.atamyo.com

Contact U.S. :

Charles Craig, Opus Biotech Communications

charles.s.craig@gmail.com, 404-245-0591

Contact en Europe: contact@atamyo.com

Atamyo Therapeutics Announces Scientific Communications on its LGMD Programs and Participation in Conferences

Posted on by admin_ata
  • Five upcoming communications on LGMD programs at Myology 2024 Congress
  • CEO Stephane Degove to present corporate overview at BioEquity Europe 2024

Evry, France (April 22, 2024) – Atamyo Therapeutics, a clinical-stage biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced its participation in upcoming  conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

Five upcoming communications at the 8th International Myology Congress (April 22-25, 2024 in Paris, France).

Five communications describing Atamyo’s LGMD programs will be presented at the 8th International Myology Congress:

1) Development of gene therapy for three prevalent forms of LGMD

. Oral Presentation by E. Giquel (Genethon), at Havane Amphitheatre, on April 24, 2024, 11h00

2) Heart toxicity can be induced in rats after injection of high level of AAV expressing γ–sarcoglycan using the Desmin and MHCK7 but can be prevented by the tMCK promoter

. J Poupiot (Genethon) et al., poster number P331, Therapeutics session

3) Evaluation of gene transfer efficiency in a mild model of dystrophic muscle disorder performed by machine learning and linear discriminant analysis

. A Brureau (Genethon) et al., poster number P117, Muscle Function session

4) Lipid metabolism is disrupted in mouse and human models of FKRP deficiency, and rescued after FKRP gene transfer

. E Gicquel (Genethon) et al., poster number P296, Muscular Dystrophy session

5) FKRP related Limb Girdle Muscular Dystrophy: A biomarker identification study

. S Campuzano (Genethon) et al., poster number P293, Muscular Dystrophy session

Atamyo to participate in BioEquity Europe Conference (May 12-14 in San Sebastian, Spain).

Stephane Degove, Atamyo CEO, will provide a corporate overview during an oral presentation on May 14, at 11:20 AM, in the Room 4+5.

About Atamyo Therapeutics

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD2I/R9 and LGMD2C/R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

For more information visit www.atamyo.com

U.S. Contact:

Charles Craig, Opus Biotech Communications

Charles.s.craig@gmail.com, 404-245-0591

European contact: contact@atmayo.com

Atamyo Therapeutics Announces participations in Conferences and Key Scientific Communications on its LGMD programs

Posted on by admin_ata
  • Participation in Chardan’s 7th Genetic Medicines Conference
  • Participation in Cell and Gene Therapy on the Mesa 2023 Meeting
  • Five upcoming communications on LGMD programs at WMS congress, ESGCT annual meeting and 2023 International Limb-Girdle Muscular Dystrophy Conference

Evry, France (September 29, 2023) – Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

Atamyo to participate in Chardan’s 7th Annual Genetic Medicines Conference and in Cell & Gene Meeting on the Mesa 2023

Stephane Degove, Atamyo CEO, will provide a corporate overview at two forthcoming conferences in October:

  • Chardan’s 7th Annual Genetic Medicines Conference, held in New York City:
  • Presentation on October 2, at 10:30 AM, in the Embassy room
  • Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, on October 10-12, 2023:
  • Presentation on October 10, at 5:15pm, at the Rentschler ATMP Ballroom

Two upcoming communications at the 28th Annual Congress of the World Muscle Society (3-7 October 2023 in Charleston, SC)

Two communications describing Atamyo’s LGMD programs will be presented by Atamyo and Genethon at the 28th International Annual Congress of the World Muscle Society (WMS):

1. Evaluation of gene transfer efficiency in a mild model of dystrophic muscle disorder performed by machine learning and linear discriminant analysis

  • Oral Presentation by A. Brureau (Genethon), at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
  • Poster Board Number 282 at Ballroom C, on October 4, 2023, 17h15-18h15

2. Natural history of limb girdle muscular dystrophy R9: one-year follow-up of a European cohort

  • Oral Presentation by J. Vissing (Copenhagen Neuromuscular Center, Rigshospitale) at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
  • Poster Board Number 283 at Ballroom C, on October 4, 2023, 17h15-18h15

Two upcoming communications at the European Society of Gene & Cell Therapy 30th annual congress (24-27 October 2023 in Brussels – Belgium):

Two communications describing Atamyo’s LGMD programs will be presented by Atamyo and Genethon at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) that will take place on October 24-27, 2023 in Brussel (Belgium):

1) Gene therapy for LGMDR9: preliminary results of a dose-escalation study

  • Oral presentation by Nicolai Preisler, MD, Rigshospitalet, Copenhagen, during the Cardiovascular and muscular diseases session, on Friday October 27, 11h30-13h00 – Le BEL, Tour & Taxis

2) A micro-RNA regulated AAV vector prevents the cardiotoxicity induced by transgene overexpression following FKRP gene transfer

  • E. Gicquel (Genethon) et al., poster number P060, poster sessions October 25 and 26

Oral presentation on Atamyo’s LGMD-R9 program at the 2023 International Limb-Girdle Muscular Dystrophy Conference (28-29 October 2023, Washington DC)

  1. Preliminary experiences with Atamyo’s FKRP gene therapy
  • Oral presentation by John Vissing, MD, Rigshospitalet, Copenhagen, during the Clinical Trials Updates (Part 1) Session, on October 29, 11h00am-12h10pm – Constitution Ballroom, Grand Hyatt

About Atamyo Therapeutics

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. For more information visit www.atamyo.com

U.S. Contact:

Charles Craig, Opus Biotech Communications

charles.s.craig@gmail.com, 404-245-0591

European contact: contact@atamyo.com